Towards the implementation of a continuous bioprocess in single use technology
September 17-21, 2017
Bayer has developed a new production technology for monoclonal antibodies based on single use equipment and continuous processing. The development is referred to as the MoBiDiK project (Modular, Biologics, Disposable and Continuous) and was presented at the ICB 1 and ICB 2 conferences. At the ICB 3 conference we will focus on the topics that are critical to the implementation of the technology in a GMP production environment. These are: Process robustness, GMP readiness of the equipment, automation as well as process control and product release strategies.
Jorgen Magnus, Maike Temming, Peter Schwan, Viktorija Kistler, Stefan Sievers, Martin Poggel, Thomas Daszkowski, and Martin Lobedann, "Towards the implementation of a continuous bioprocess in single use technology" in "Integrated Continuous Biomanufacturing III", Suzanne Farid, University College London, United Kingdom Chetan Goudar, Amgen, USA Paula Alves, IBET, Portugal Veena Warikoo, Axcella Health, Inc., USA Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/biomanufact_iii/74
This document is currently not available here.